autologous hematopoietic stem cell transplantation

Autologous hematopoietic stem cell transplant (aHSCT), a procedure that aims to “reset” the immune system, generally reduces disability and relapse rates in people with multiple sclerosis (MS), according to a new meta-analysis. “Current data encourage a broader application of AHSCT for treating patients with MS while still considering…

Undergoing a stem cell transplant, a procedure that aims to “reset” a person’s immune system, can reduce relapse rates and ease disability in people with multiple sclerosis (MS), new data show. The findings suggest that such a transplant — fully, autologous hematopoietic stem cell transplantation or aHSCT — is…

A small group of multiple sclerosis (MS) patients with aggressive disease, who were treated with hematopoietic stem cell transplant in a clinical trial, reported a drop in their fatigue levels that researchers suggested was likely due to lesser inflammation. The study, “Autologous hematopoietic stem cell transplantation improves…

Stem cell transplants are most effective if done in young multiple sclerosis (MS) patients in early disease stages, who have not gone through several rounds of other treatments, according to a large study that followed transplant patients for more than five years. Study results also found that people with relapsing MS are much…

A high fraction of patients with multiple sclerosis (MS) who underwent a transplant with their own bone marrow stem cells after immunosupression therapy, show no signs of disease activity after treatment, according to a new study. The results were presented in a talk, “Clinical experience in aggressive multiple sclerosis treatment with…

On the second day of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress Sept. 14-17 in London, researchers shared their views on bone marrow transplants for relapsing forms of multiple sclerosis (MS). The debate, “Bone marrow transplantation is a justifiable treatment for active relapsing…